Observational studyArchives of gynecology and obstetrics2026
Safety and effectiveness of etonogestrel implant in Chinese women requiring contraception: a multicenter, prospective, observational study.
Observational study in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the overall safety and effectiveness of the etonogestrel implant radiopaque in real-world clinical settings in China.
methodsA multicenter, prospective, single-arm, observational study was conducted in women (aged ≥ 18 years) across 31 centers in China (March 2016-July 2021). The implant was prescribed as part of routine clinical practice. Primary outcomes included overall safety and topical (local) safety profile; secondary outcomes included participant and physician satisfaction and contraceptive effectiveness of the etonogestrel implant.
resultsOf 1,901 women using the etonogestrel implant, 45.5% completed the 3-year study. The mean (SD) age of the women was 32.1 (5.6) years and the mean (SD) implant exposure duration was 783.7 (388.7) days. Overall, 47.9% reported drug-related adverse events (AEs; excluding topical AEs), 1.1% reported serious AEs, and 10.4% reported topical AEs after insertion. Vaginal bleeding (15.6%) was the most frequent drug-related AE. At 36 months after insertion or upon removal, most women were satisfied (38.9%) or very satisfied (23.7%) with the implant. Among 96 physicians who completed questionnaires following the first insertion, 57.3% were very satisfied and 38.5% were satisfied. Most (98.9%) of the physicians reported satisfaction following their first removal procedure. Of them, 65.3% were very satisfied and 33.7% were satisfied. One (1.1%) physician was neither satisfied nor dissatisfied. One (0.05%) in-treatment pregnancy was reported.
conclusionSafety findings from this study in China's real-world clinical setting were consistent with the clinical development program without unexpected safety signals. Observed contraceptive effectiveness was consistent with established evidence for the implant, with general satisfaction reported among Chinese women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.